What is Sana Biotechnology, Inc. (SANA) stock price today?

Sana Biotechnology, Inc. (SANA) is currently trading at $2.79, up 0% today.

What is SANA P/E ratio?

Sana Biotechnology, Inc.'s P/E ratio is -3.80. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is SANA return on equity (ROE)?

Sana Biotechnology, Inc.'s return on equity (ROE) is -134.49%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Sana Biotechnology, Inc.'s market cap?

Sana Biotechnology, Inc. has a market capitalization of $776.43M.

NASDAQ · Biotechnology

Sana Biotechnology, Inc. (SANA) Stock

$2.79 +0.00% NASDAQ: SANA Healthcare

Valuation

Metric	Value
Price	$2.79
Market Cap	$776.43M
P/E Ratio	-3.80
P/B Ratio	5.53
P/S Ratio	0.00
EPS (TTM)	$-0.96
52-Week High	$6.55
52-Week Low	$2.61
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-134.49%
ROA	-49.09%
ROCE	-67.58%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.48
Current Ratio	1.89

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-357.0M	$-273.0M	$-293.0M	$-273.0M	$-191.0M
Net Profit	$-356.0M	$-269.0M	$-283.0M	$-267.0M	$-244.0M
EPS	$-2.14	$-1.43	$-1.46	$-1.16	$-0.96
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$1.1B	$823.0M	$565.0M	$501.0M	$417.0M
Total Liabilities	$401.0M	$323.0M	$278.0M	$251.0M	$256.0M
Cash	$253.0M	$177.0M	$134.0M	$128.0M	$72.0M
Borrowings	$111.0M	$108.0M	$104.0M	$94.0M	$79.0M

Latest News

3 Promising Genomics Stocks to Add to Your Portfolio in 2026 Zacks · Jul 20, 2026 Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM Simply Wall St. · Jul 16, 2026 Sana (SANA) Upgraded to Buy: Here's What You Should Know Zacks · Jul 15, 2026 Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes GlobeNewswire · Jul 13, 2026 Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 GlobeNewswire · Jul 1, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-251.0M	$-290.0M	$-254.0M	$-223.0M	$-144.0M
Investing Cash Flow	$-276.0M	$190.0M	$152.0M	$-16.0M	$-41.0M
Financing Cash Flow	$0	$0	$0	$-181.0M	$0
Net Cash Flow	$135.0M	$-75.0M	$-50.0M	$-6.0M	$-55.0M
Free Cash Flow	$-281.0M	$-311.0M	$-274.0M	$-257.0M	$-145.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.11
EV / EBITDA	-4.08
FCF Yield	-16.79%
Quick Ratio	1.38
Interest Coverage	0.00
Return 1Y	-37.55%
Return 3Y	-46.32%
Return 5Y	-79.86%

Ownership

Insiders Held6.51%

Institutions Held82.85%

Institutions Float Held88.62%

Institutional Holder	Shares	Report Date
FMR, LLC	37,430,284	2026-03-31
Flagship Pioneering LLC	25,001,856	2026-03-31
Blackrock Inc.	14,240,175	2026-03-31
State Street Corporation	10,538,086	2026-03-31
Canada Pension Plan Investment Board	10,221,900	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALLOAllogene Therapeutics, Inc.	$1.46	+4.29%	-2.24	$503.96M	0.00%
ATRAAtara Biotherapeutics, Inc.	$9.48	+2.71%	-7.94	$85.42M	0.00%
BEAMBeam Therapeutics Inc.	$25.90	+5.30%	-29.88	$2.67B	0.00%
CGEMCullinan Therapeutics, Inc.	$15.53	+0.45%	-4.60	$954.44M	0.00%
CRSPCRISPR Therapeutics AG	$53.39	+5.85%	-11.62	$5.15B	0.00%

About Sana Biotechnology, Inc.

Sana Biotechnology, Inc. is led by CEO Steven D. Harr, employs 194 people, headquartered in US, publicly traded since 2021.

Sana Biotechnology, Inc. (SANA) stock trades at $2.79 with a market capitalization of $776.43M. The stock is valued at a price-to-earnings (P/E) ratio of -3.80, price-to-book of 5.53, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.61 and $6.55, and currently trades 57.4% below its 52-week high.

On profitability, Sana Biotechnology, Inc. generates a return on equity (ROE) of -134.49%, return on capital employed of -67.58%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides